• If you are wondering whether Ionis Pharmaceuticals at around US$74.24 is offering fair value or not, it helps to look past the headline price and focus on what different valuation tools are signaling.
• The stock has had a mixed recent run, with a 4.1% gain over the last 7 days, a 13.1% decline over 30 days and a 6.8% decline year to date, set against a 134.0% return over 1 year, 112.8% over 3 years and 64.8% over 5 years.
• Recent coverage has centered on Ionis Pharmaceuticals' role in the biotech space, including its progress as a pharmaceuticals and biotech company listed on the Nasdaq and how that fits into investor expectations for the sector. This context helps frame why the share price has moved sharply over different time frames and why valuation has become a key talking point.
• Ionis currently has a valuation score of 2 out of 6, so the next sections will walk through what that means across various valuation approaches, before finishing with a more complete way to think about what the stock might be worth.

Ionis Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Ionis Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of a company’s future cash flows and discounts them back to today, aiming to translate those projections into a single present value per share.

For Ionis Pharmaceuticals, the DCF used here is a 2 Stage Free Cash Flow to Equity model based on cash flow projections in $. The latest twelve month free cash flow is a loss of $321.0 million, and analysts’ inputs plus extrapolations extend out to 2035. Within that path, the model includes a projected free cash flow of $848.4 million in 2030, with earlier years such as 2026 and 2027 still showing negative free cash flow before moving into positive territory.

Bringing all those projected cash flows back to today produces an estimated intrinsic value of about $260.78 per share, compared with the recent share price of around $74.24. On this basis, the DCF suggests the stock trades at roughly a 71.5% discount to its estimated value, which is a large gap.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Ionis Pharmaceuticals is undervalued by 71.5%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.

Approach 2: Ionis Pharmaceuticals Price vs Sales

For companies where earnings are not yet a steady guide, price to sales is often a useful cross check because it compares what you pay for each dollar of revenue, rather than profit that can swing with R&D and one off items.

What counts as a “normal” or “fair” P/S multiple tends to rise when investors expect stronger growth and accept higher risk, and tends to be lower when growth expectations are more muted or risks are seen as higher than average.

Ionis Pharmaceuticals currently trades on a P/S of 13.00x, compared with the Biotechs industry average of 10.79x and a peer group average of 4.07x. Simply Wall St’s Fair Ratio for Ionis, at 5.17x, is a proprietary estimate of what the P/S might be given factors such as its earnings profile, margins, industry, market value and risk characteristics. This Fair Ratio can be more tailored than a simple peer or industry comparison because it weights company specific features rather than treating all biotechs as alike.

Set against that Fair Ratio of 5.17x, the current 13.00x P/S suggests the shares are trading above that tailored reference point.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Ionis Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so here is an introduction to Narratives, a simple way for you to write the story you believe about Ionis Pharmaceuticals and connect that story to concrete numbers such as future revenue, earnings, margins and a fair value that you can compare with the current share price.

On Simply Wall St’s Community page, Narratives let you link Ionis’ business story to a full forecast and fair value. You can then see how that stacks up against other views, such as a higher fair value of US$116.76 or a lower one of about US$62.78. This allows you to quickly see how different assumptions lead to different opinions about whether the current price looks high or low.

Because these Narratives refresh when new news or earnings arrive, you can see your fair value update alongside the consensus target of US$93.90 and the lowest and highest analyst targets of US$43.00 and US$96.00. This helps you decide if Ionis still fits your thesis or if the gap between price and your fair value has moved enough to reconsider your next step.

For Ionis Pharmaceuticals, however, we'll make it really easy for you with previews of two leading Ionis Pharmaceuticals Narratives:

Fair value: US$93.90

Gap to fair value: around 20.9% below this narrative fair value at the recent US$74.24 share price

Revenue growth assumption: 25.0% a year

• Focuses on Ionis building out from rare diseases into larger patient groups, with physicians showing strong acceptance of its RNA targeted medicines.
• Highlights growing royalty and milestone income from partners such as Biogen, AstraZeneca and Roche as an important support for financial resilience.
• Flags risks around pricing pressure, dependence on a small number of late stage programs and partner execution, which could affect margins and revenue progression.

Fair value: US$62.78

Gap to fair value: around 18.2% above this narrative fair value at the recent US$74.24 share price

Revenue growth assumption: 13.8% a year

• Emphasises pricing pressure as Ionis moves from high priced orphan indications to broader conditions where payers tend to accept lower per patient spending.
• Points to higher R&D and commercial costs, together with competition in RNA and genetic medicines, as reasons earnings could remain under pressure.
• Also acknowledges that partnerships, an active late stage pipeline and improving guidance could limit downside if launches and clinical milestones go to plan.

Do you think there's more to the story for Ionis Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.